following a full submission:
daclizumab (Zinbryta®) is accepted for restricted use within NHS Scotland.
Indication under review: In adult patients for the treatment of relapsing forms of multiple sclerosis.
Restriction: for use
• in patients with rapidly evolving severe (RES) relapsing remitting multiple sclerosis (RRMS) or
• in patients with RRMS with an inadequate response to disease modifying therapy
In a phase III study, the adjusted annualised relapse rate (over a period of 144 weeks) was statistically significantly lower for daclizumab than for an interferon beta treatment in patients with RRMS.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of daclizumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
|Drug Name:||daclizumab (Zinbryta)|
|SMC Drug ID:||1216/17|
|Manufacturer:||Biogen Idec Ltd|
|Indication:||In adult patients for the treatment of relapsing forms of multiple sclerosis.|
|Sub Category:||8.2 Drugs affecting the immune response|
|Submission Type:||Full submission|
|Date Advice Published:||10 April 2017|